X4 Pharmaceuticals, Inc of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2015-06-05. The offering totals $20.0M, of which $20.0M was reported sold. Industry: Biotechnology.
Showing 25 of 72 people.
| Name | Role | Location |
|---|---|---|
| CARL GORDON | Director | SAN DIEGO, CA |
| Michael Ross | Director | South San Francisco, CA |
| Amy Schulman | Director | Cambridge, MA |
| Michael Gray | Executive Officer | Vancouver, A1 |
| Mary DiBiase | Executive Officer | BOSTON, MA |
| Murray W Stewart | Director | BOSTON, MA |
| Christophe Arbet-Engels | Executive Officer | BOSTON, MA |
| David Kirske | Executive Officer | BOSTON, MA |
| Michael S Wyzga | Director | BOSTON, MA |
| John Volpone | Executive Officer | BOSTON, MA |
| Mark Baldry | Executive Officer | BOSTON, MA |
| Francoise J De Craecker | Director | BOSTON, MA |
| Gary J Bridger | Director | BOSTON, MA |
| Adam Craig | Director | BOSTON, MA |
| Adam Craig | Executive Officer | BOSTON, MA |
| Claudio Nessi | Director | Philadelphia, PA |
| Adam Mostafa | Executive Officer | Toronto, A6 |
| David McGirr | Director | Boston, MA |
| Francoise de Craecker | Director | Boston, MA |
| Michael Wyzga | Director | Boston, MA |
| Arthur Taveras | Executive Officer | Boston, MA |
| Murray Stewart | Director | Boston, MA |
| Murray Stewart | Executive Officer | Boston, MA |
| William Aliski | Director | Novato, CA |
| Alison Lawton | Director | Boston, MA |
| Filed | Form | Offering | Sold |
|---|---|---|---|
| 2025-08-25 | D | $85.0M | $85.0M |
| 2023-06-01 | D | $65.0M | $65.0M |
| 2022-07-19 | D | $111.5M | $55.7M |
| 2017-12-04 | D | $20.0M | $20.0M |
| 2017-05-08 | D | $50.5M | $45.5M |
| 2016-04-27 | D | $15.0M | $15.0M |
| 2015-12-30 | D | $4.0M | $4.0M |
| 2014-08-11 | D/A | $20.0M | $13.0M |
| 2013-08-13 | D | $20.0M | $13.0M |
| 2011-02-07 | D | $9.6M | $9.6M |
| 2010-09-24 | D | $400K | $400K |